Burton R L, Antonello J, Cooper D, Goldblatt D, Kim K H, Plikaytis B D, Roalfe L, Wauters D, Williams F, Xie G L, Nahm M H, Akkoyunlu M
Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Department of Biometrics Research, Merck & Co., Inc., West Point, Pennsylvania, USA.
Clin Vaccine Immunol. 2017 Feb 6;24(2). doi: 10.1128/CVI.00457-16. Print 2017 Feb.
Opsonophagocytic assays (OPAs) are routinely used for assessing the immunogenicity of pneumococcal vaccines, with OPA data often being utilized for licensure of new vaccine formulations. However, no reference serum for pneumococcal OPAs is available, making evaluation of data among different laboratories difficult. This international collaboration was initiated to (i) assign consensus opsonic indexes (OIs) to FDA pneumococcal reference serum lot 007sp (here referred to as 007sp) and a panel of serum samples used for calibration of the OPA and (ii) determine if the normalization of the OPA results obtained with test samples to those obtained with 007sp decreases the variability in OPA results among laboratories. To meet these goals, six participating laboratories tested a panel of serum samples in five runs for 13 serotypes. For each serum sample, consensus OIs were obtained using a mixed-effects analysis of variance model. For the calibration serum samples, normalized consensus values were also determined on the basis of the results obtained with 007sp. For each serotype, the overall reduction in interlaboratory variability was calculated by comparing the coefficients of variation of the unadjusted and the normalized values. Normalization of the results substantially reduced the interlaboratory variability, ranging from a 15% reduction in variability for serotype 9V to a 64% reduction for serotype 7F. Normalization also increased the proportion of data within 2-fold of the consensus value from approximately 70% (average for all serotypes) to >90%. On the basis of the data obtained in this study, pneumococcal reference standard lot 007sp will likely be a useful reagent for the normalization of pneumococcal OPA results from different laboratories. The data also support the use of the 16 FDA serum samples used for calibration of the OPA as part of the initial evaluation of new assays or periodic assessment of established assays.
调理吞噬试验(OPAs)通常用于评估肺炎球菌疫苗的免疫原性,OPAs数据常被用于新疫苗配方的许可。然而,目前尚无用于肺炎球菌OPAs的参考血清,这使得不同实验室之间的数据评估变得困难。发起这项国际合作是为了:(i)为美国食品药品监督管理局(FDA)肺炎球菌参考血清批次007sp(以下简称007sp)以及用于校准OPAs的一组血清样本指定共识调理指数(OIs);(ii)确定将测试样本获得的OPAs结果与007sp获得的结果进行标准化处理是否会降低各实验室间OPAs结果的变异性。为实现这些目标,六个参与实验室对一组血清样本进行了五轮测试,涉及13种血清型。对于每个血清样本,使用方差混合效应分析模型获得共识OIs。对于校准血清样本,还根据007sp获得的结果确定了标准化共识值。对于每种血清型,通过比较未调整值和标准化值的变异系数来计算实验室间变异性的总体降低情况。结果的标准化显著降低了实验室间的变异性,变异性降低幅度从9V血清型的15%到7F血清型的64%不等。标准化还使在共识值2倍范围内的数据比例从约70%(所有血清型的平均值)增加到>90%。基于本研究获得的数据,肺炎球菌参考标准批次007sp可能是用于标准化不同实验室肺炎球菌OPAs结果的有用试剂。这些数据还支持将用于校准OPAs的16个FDA血清样本用作新检测方法初始评估或既定检测方法定期评估的一部分。